Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
Abstract Increasing evidence has shown that Chinese herbal medicine (CHM) has promising therapeutic effects in colorectal cancer (CRC); however, the active ingredients and potential targets remain unclear. In this study, we aimed to investigate the relative molecular targets of the Chinese herbs tha...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2018-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-018-25500-x |
| _version_ | 1818995091148111872 |
|---|---|
| author | Hongxu Zhu Jian Hao Yangyang Niu Dan Liu Dan Chen Xiongzhi Wu |
| author_facet | Hongxu Zhu Jian Hao Yangyang Niu Dan Liu Dan Chen Xiongzhi Wu |
| author_sort | Hongxu Zhu |
| collection | DOAJ |
| description | Abstract Increasing evidence has shown that Chinese herbal medicine (CHM) has promising therapeutic effects in colorectal cancer (CRC); however, the active ingredients and potential targets remain unclear. In this study, we aimed to investigate the relative molecular targets of the Chinese herbs that have been found effective in treating metastatic CRC (mCRC) based on clinical data and network pharmacology. In multivariate analysis CHM resulted an independent prognostic factor. The hazard ratio was 0.103 (95% confidence interval = 0.064–0.164; P < 0.001). Compared with the non-CHM group, the median survival time of the CHM group was also improved (40 versus 12 months; P < 0.001). Eighteen out of 295 herbs showed significant correlation with survival results (P < 0.05). Bioinformatics analysis indicated that the 18 herbs realize anti-CRC activity mainly through suppressing the proliferative activity of ERBB2, peroxisome proliferator-activated receptor gamma, and retinoid X receptor, suppressing angiogenesis via inhibition of VEGFR and VEGFA expression, inhibiting the phosphatidylinositol-3-kinase/AKT1 signaling pathway directly through SRC and AKT1, and reducing tumor necrosis factor-induced inflammation. |
| first_indexed | 2024-12-20T21:08:20Z |
| format | Article |
| id | doaj.art-ada55a25927e4f579ffc749cc3c3fe0e |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-20T21:08:20Z |
| publishDate | 2018-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-ada55a25927e4f579ffc749cc3c3fe0e2022-12-21T19:26:34ZengNature PortfolioScientific Reports2045-23222018-05-018111210.1038/s41598-018-25500-xMolecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacologyHongxu Zhu0Jian Hao1Yangyang Niu2Dan Liu3Dan Chen4Xiongzhi Wu5Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Children’s HospitalTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyDepartment of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, TianjinZhong-Shan-Men Inpatient Department, Tianjin Medical University Cancer Institute and HospitalAbstract Increasing evidence has shown that Chinese herbal medicine (CHM) has promising therapeutic effects in colorectal cancer (CRC); however, the active ingredients and potential targets remain unclear. In this study, we aimed to investigate the relative molecular targets of the Chinese herbs that have been found effective in treating metastatic CRC (mCRC) based on clinical data and network pharmacology. In multivariate analysis CHM resulted an independent prognostic factor. The hazard ratio was 0.103 (95% confidence interval = 0.064–0.164; P < 0.001). Compared with the non-CHM group, the median survival time of the CHM group was also improved (40 versus 12 months; P < 0.001). Eighteen out of 295 herbs showed significant correlation with survival results (P < 0.05). Bioinformatics analysis indicated that the 18 herbs realize anti-CRC activity mainly through suppressing the proliferative activity of ERBB2, peroxisome proliferator-activated receptor gamma, and retinoid X receptor, suppressing angiogenesis via inhibition of VEGFR and VEGFA expression, inhibiting the phosphatidylinositol-3-kinase/AKT1 signaling pathway directly through SRC and AKT1, and reducing tumor necrosis factor-induced inflammation.https://doi.org/10.1038/s41598-018-25500-x |
| spellingShingle | Hongxu Zhu Jian Hao Yangyang Niu Dan Liu Dan Chen Xiongzhi Wu Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology Scientific Reports |
| title | Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology |
| title_full | Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology |
| title_fullStr | Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology |
| title_full_unstemmed | Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology |
| title_short | Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology |
| title_sort | molecular targets of chinese herbs a clinical study of metastatic colorectal cancer based on network pharmacology |
| url | https://doi.org/10.1038/s41598-018-25500-x |
| work_keys_str_mv | AT hongxuzhu moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology AT jianhao moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology AT yangyangniu moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology AT danliu moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology AT danchen moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology AT xiongzhiwu moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology |